YEARS
OF SERVING PATIENTS
Dr. Reddy's Laboratories Limited
Integrated Annual Report 2023-24
Contents
Corporate Overview
- 40 Years of Serving Patients
- Our 40-Year Journey
- Who We Are
- Message from Chairman and Co-Chairman & MD
- Our Global Presence
- Key Performance Indicators
-
Highlights of the Year 14 In Pictures
16 Awards and Recognitions
- Board of Directors
- Management Council
Strategy and Sustainability
- About Our Reporting Approach
- Our Strategy Pillars
- Our Value Creation Model
-
Our ESG Goals
32 Access, Affordability and Innovation for Patients
36 Helping our People Realise Their Full Potential
40 Empowering the Communities Around Us
44 Commitment to Environmental Stewardship
50 Enhancing Trust with our Stakeholders
- Stakeholder Engagement and Materiality Assessment
- Risk Management
Statutory Reports
66 Management Discussion and Analysis
- Five years at a Glance and Key Financial Ratios
- Board's Report and Annexures
- Business Responsibility and Sustainability Report
- Corporate Governance Report
- Additional Shareholders' Information
Financial Statements
211 Standalone Financial Statements (Ind AS) |
306 Consolidated Financial Statements (Ind AS) |
06-07 Who We Are
30-59 Our ESG Progress
40 YEARS
OFSERVINGPATIENTS
419 Extract of IFRS Consolidated Financial Statements |
Annexures
- Independent Assurance Statement
- GRI Index
- Glossary
- Notice of 40th Annual General Meeting
Click on any section title to go directly to that part of the document.
66-79 Management
Discussion and Analysis
For four decades, we have stood foradvancing healthcare throughaccess, affordability and innovation. Our work has been guided byour core tenets of deep science, progressive people practicesand robust governance. 'GoodHealth Can't Wait' has become a movement and call to action for all of us, and good health encompasses people, planet and patients. We are grateful
for the trust our patients and stakeholders have had in us throughout our journey.
As the pharmaceutical industry evolves, we will
continue to work on strengthening our core further and building the future of healthcare as we aim to touch the lives of over 1.5 billion patients by 2030.
Our second Integrated Report combines our Annual Report and our Sustainability Report to present a holistic view of our Company and how we create value for patients and other stakeholders.
Our40-YearJourney
Integrated Annual Report 2023-24
1992
Corporate Overview | Strategic Review | Statutory Reports | Financial Statements |
2003
y We released our first Safety, |
Health, Environment (SHE) |
1984
Dr. Anji Reddy established Dr. Reddy's Laboratories Ltd.
1986
- We went public and were listed on the Bombay Stock Exchange
- We launched certain APIs for the first time in India
- In the 1980s, we were among the earliest Indian pharma companies to export APIs to USA at scale
We expanded our operations internationally by opening a
branch in Russia
1996
Dr. Anji Reddy founded the Dr. Reddy's Foundation (DRF) to give back
to society. Today, our Company's CSR activities include work in health, education, livelihood and environmental sustainability
2001
- We became the first pharma company in Asia outside Japan to list on the New York Stock Exchange
-
We became the first Indian pharma company to obtain
180-day marketing exclusivity from the USFDA (for Fluoxetine capsules 40 mg) - We pioneered the concept of 'Self-Managed Teams' in Indian pharma to provide skilling and livelihood opportunities to youths around our plant sites
report. In 2004, we were |
also among the earliest to |
initiate annual voluntary |
sustainability disclosures |
y Led the way in building a Zero |
Liquid Discharge (ZLD) plant |
based on membrane technology |
in Miryalaguda to treat and |
recycle all effluents in-house |
1985
Our first API factory in Bollaram, Hyderabad, commenced operation
1991
Our first mega-brand Omez (Omeprazole) was launched in India, and went on to become our first ` 1 bn brand and a leader in Indian pharma
1993
We were among the earliest in Indian pharma to initiate new drug discovery through the Dr. Reddy's Research Foundation
1997
We were the first Indian pharma company to out-license a novel drug to an innovator
2002
Aurigene Discovery Technologies Ltd (today, Aurigene Oncology Ltd), our subsidiary in Bengaluru, was incorporated for new drug discovery
02 | 03 |
2006
Integrated Annual Report 2023-24
Corporate Overview | Strategic Review | Statutory Reports | Financial Statements |
2024
y We diversified our offerings to patients |
- women's healthcare in the U.S., |
consumer healthcare and our first-ever |
- We crossed US$ 1 bn in revenue
-
We became the first Indian pharma company to launch
Authorized Generics (AG) in the U.S. (finasteride 5mg, generic equivalent of Merck's Proscar tabs; and simvastatin in various strengths, generic equivalent of Merck's Zocor tabs)
2010
- We launched the world's then first and India's only generic of darbepoetin alfa (Cresp) in India
- We adopted 6 sustainability goals for the next decade
2019
We became the first foreign generics company to receive approval to supply an existing product (Olanzapine)
to China's public hospitals under the QCE system
2021
Our Company played its part along with the rest of the pharma industry in the fight against COVID-19
We combined our in-house efforts with an open-innovation model of partnerships to make available a portfolio that included a vaccine, and therapeutics for mild, moderate and severe COVID-19
Our focus on agility, access and affordability helped us reach over 5 mn patients during the pandemic, especially in low and middle income countries
biosimilar in the UK, and vaccines in India |
y We entered into an agreement with |
Nestlé India to form a joint venture to |
introduce health science nutraceutical |
products to consumers across India and |
other agreed territories |
HOME >>BRAND-MARKETING >>NESTLE-INDIA-AND-DR-REDDYS-FORM-JV-TO-BRING-NUTRACEUTICAL-BRANDS-TO-CONSUMERS-ACROSS-
Nestlé India and Dr. Reddy's form JV to bring nutraceutical brands to consumers across India
e partnership will bring together the Āell-known global range of nutritional health solutions as well as vitamin, minerals, herbals and supplements of Nestlé Health Science (NHSc) with the strong and established commercial strengths of Dr. Reddy's in India.
Printed from
Dr Reddy's to exclusively distribute Sanofi's vaccine portfolio in India
TNN | Mar 27, 2024, 08.13 PM IST
HYDERABAD: Dr Reddy's Laboratories on Wednesday informed the bourses has entered into an exclusive partnership with Sanofi Healthcare India Pvt Ltd for the distribution of the latter's vaccine portfolio in the Indian market.
As part of the agreement, while Dr Reddy's will have exclusive rights to promote and distribute Sanofi's paediatric and adult vaccine brands in India, Sanofi will continue to own, manufacture, and import these brands to the country.
These include paediatric and adult vaccine brands such as Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U. These brands rang up combined sales of around Rs 426 crore (approx. US$51 million), as per IQVIA MAT February 2024.
The Hyderabad-based pharma major said the partnership is part of Dr Reddy's efforts to emerge as the partner of
2007
We launched the monoclonal antibody biosimilar of rituximab in India (Reditux)
2016
We were listed on the Dow Jones Sustainability Index 2016 for Emerging Markets for the first time
2020
We became the first pharma company in India and third in Asia to join the Science-Based targets initiative (SBTi)
2022
- Our biggest manufacturing facility in Hyderabad was recognised by the World Economic Forum as part of its Global Lighthouse Network for leadership in the use of Industry 4.0 technologies
- Dr. Reddy's Foundation received a National Award from the President of India for Empowerment of Persons with Disabilities
- We refreshed our ESG goals to make them bold, measurable, accountable and central to business strategy
-
We were named by the prestigious
Science Magazine as among the Top 20 employers globally in pharma/biotech - We launched Lenalidomide Capsules in the U.S. with two of six strengths eligible for first-to-file,180-day exclusivity
2023
- We became the first Indian pharma company to debut on the Dow Jones Sustainability World Index
- We launched Nerivio® in India for migraine management, marking our foray into digital therapeutics
- We entered into strategic collaborations for novel molecules - with the U.S.-based Coya Therapeutics for a novel combination biologic for ALS; with China-based Junshi Biosciences for Toripalimab; and with Jiangsu Hengrui for Pyrotinib
- We were included in the Bloomberg Gender-Equality Index for the 6th year in a row
04 | 05 |
Integrated Annual Report 2023-24
Who We Are
Our Purpose
We accelerate access to affordable and innovative medicines because Good Health Can'tWait
Corporate Overview | Strategic Review | Statutory Reports | Financial Statements |
Our Values
In pursuit of our purpose of providingaffordable and innovative medicines for healthier lives, we will create an environment of innovation and learning while continually reaching for higher levels of excellence
Our Promises
Bringing | Addressing | Helping | Working | Enabling |
expensive | unmet patient | patients manage | with partners | and helping our partners |
medicines | needs | disease better | to help them | ensure that our medicines |
within reach | succeed | are available where needed |
Integrity and Transparency
We will uphold the highest standards of integrity and transparency in all our transactions
Respect for the Individual
We are committed to creating a work environment that encourages diverse perspectives and upholds the dignity of work and of individuals
Safety | Quality | Productivity |
We are committed to providing | We are dedicated | We strive to achieve |
safe working environments | to designing quality | more with less through |
through continuous improvement | into our products and | a culture of innovation, |
of our infrastructure, work | processes to delight | continuous improvement |
practices and behaviours | our stakeholders | and a substantial focus |
on elimination of waste |
Collaboration and Teamwork | Sustainability |
We will leverage expertise and | We will create value for our stakeholders |
resources from across our | in a manner that respects our natural |
global network to create greater | environment and serves the best |
value for our stakeholders | interests of the communities in which |
we live and work |
Our Leadership Behaviours
Our Principles
Empathy | Dynamism |
We understand | We solve challenges that |
the needs of our | only a few can, and do |
patients and partners | this with agility |
better than others |
06
Aspirational Growth Mindset
We target industry-leading growth through innovation, cost leadership and taking risks
Innovation
We drive patient and customer-focussed innovation in all areas using cutting-edge science, technology and tools
Speed and Rigour in Execution
We act with agility; we are disciplined and rigorous in execution
Results Driven
We take responsibility for outcomes and own end results for our patients
People Leadership
We inspire people to reach their full potential through work and continuous learning
Excellence Focus
We excel by combining deep professional expertise and disciplined execution
07
Integrated Annual Report 2023-24
Corporate Overview | Strategic Review | Statutory Reports | Financial Statements |
Message from Chairman and Co-Chairman & MD
customers, partners, and all other stakeholders. Our people are our pride, and nothing gives us more joy than to see our people realise their full potential in the company, and to see several of our alumni lead the industry forward.
There is still a long way to go.
No company can afford to rest on its past laurels. The pharma landscape continues to evolve constantly and remains extremely competitive.
Our approach is to ensure that we continue to do the basics well in our core businesses of API, generics, branded generics, biosimilars
and OTC. On the other hand, as demographics, disease patterns, business models evolve, it is important to anticipate healthcare trends of the future. We have started investing in areas that we think could be future growth drivers - novel molecules (NCEs, NBEs, CAR-T), digital therapeutics (wearables, apps), and consumer healthcare (nutrition and OTC wellness). These are relatively new and long-gestation areas requiring companies to think and do things differently through strong partnerships, investment in newer capabilities,
among vaccine players in India.
Our collaboration with Bayer in India, to market their second brand of the molecule Vericiguat, helps us make this new class of drugs in heart failure management available to patients in India, in and beyond metros in tier-I and tier-II towns. It also bolsters our heart failure management portfolio as we look to strengthen our play in the chronic segment. Our collaboration with Pharmazz Inc. enables us to market the first-in-class molecule Centhaquine in India, a potential add-on drug in the management of hypovolemic shock.
We continue to advance our work in the identified future growth spaces of access to novel molecules, digital therapeutics, and consumer healthcare. Our regulatory work in India on Toripalimab, for which we partnered with Junshi Biosciences, has moved forward. We have taken early steps in the area of digital therapeutics, with the launch of the drug-free migraine management device Nerivio®, and a digital integrated care plan to manage Irritable Bowel Syndrome (IBS). Consumer healthcare is a fast-growing segment. In recent years, we have acquired several well-known brands
names in over 30 countries outside of the U.S. We see this acquisition as an ideal anchor platform to grow our consumer healthcare business.
Through all of the above, our aim is to meet unmet needs of patients and to enhance standard of care wherever possible. We also continue our efforts to be viewed as the partner of choice for our commercial strengths and footprint, our governance, ESG and progressive practices, and
our discipline.
While our people put in every effort to ensure we meet our business targets and ESG goals, there are always challenges along the way. Our record financial performance in the last two years has been led by a blockbuster product in the U.S. We are working hard to ensure that our current investments and diversified business model approach help us maintain sustained growth in the upcoming years. As part of the usual course of business, we faced several regulatory inspections at our manufacturing sites in FY2024. Our all-time readiness approach stood us in good stead but we continue our state of constant vigilance in Quality compliance.
an initiative within our India business for working mothers from the pre-natal care stage to support in various ways until their children attain 18 years of age, thereby enabling more women to stay in the workforce and succeed in their careers. In partnership with Dr. Reddy's Foundation, we upgraded several primary healthcare centres in Srikakulam. We also completed
a pond rejuvenation community project in Baddi, and funded a rare disease research centre at the
Dr. Reddy's Institute of Life Sciences.
Over 40 years, our company has evolved from an API player to formulations, finished drugs, biosimilars, and newer healthcare segments. Amidst the evolution, what has remained unchanged is our endeavour to keep access, affordability, innovation at the heart of everything we do. And we continue to be guided by our core tenets of deep science, progressive people practices, and robust governance.
Once again, deep gratitude to all those who have supported and contributed to our journey of 40 years. It is an important milestone, but as our founder Dr. Anji Reddy often remarked, we
Dear Shareholders,
FY2024 was an exciting and eventful year. We grew our core, invested in our future, and continued to serve our stakeholders. We also observed 40 years of our company's journey. Through this second edition of our integrated report, we bring you a brief overview of our journey, important highlights of the year, and the work we do for patients, people and planet.
40 Years of Creating Value
In February 2024, we marked our 40th year of serving patients, with a legacy of access, affordability, innovation, and sustainability. Our company was founded in 1984 to enable patients to access life-saving medicines, and to use science and innovation to open new avenues to meet unmet medical needs. This pioneering spirit and quest for excellence drove us to achieve significant
industry-firsts such as investment in drug discovery in the 1990s, expansion into international markets and first-to-market launches in several countries, the first 180-day exclusivity granted to Indian pharma by the USFDA, listing on the NYSE, and adoption of voluntary disclosures and science-based commitments in sustainability.
Giving back to society was instilled into the ethos of the company from its early days.
We also learnt several lessons along the way from a myriad of challenges
- from acquisitions that did not work well, to a period of Quality compliance issues, and several geo-political crises.
We are grateful that through all the thick and thin, we had constant support and trust from our patients, the medical fraternity, shareholders and investors,
and an appetite for risk. In FY2024, we made good progress in some of these areas.
Highlights of FY2024
Overall, we delivered strong financial results in FY2024. We had double digit revenue growth at 14%, reported EBITDA margin for the year at 29.7%, and ROCE of over 35%. Our growth and profitability were driven by our performance in the U.S.
Strategic collaborations played an important role in helping us introduce the latest generation of treatments to patients in India, both in our current core business as well as future growth drivers. We signed a partnership with Sanofi in India to take their well-establishedand trusted vaccines portfolio to more people all over India. With combined sales of over ` 426 crore (as per IQVIA MAT February 2024), the vaccine portfolio also propels us to the second position
in the U.S. in Nicotine Replacement Therapy (NRT), pain-relief, and women's health. In India, we have a portfolio of OTC products in the hydration, cough-cold-allergy, and skin care categories. The recent announcement of a joint venture with Nestlé India to bring the well-known global range of nutritional health solutions as well as vitamin, minerals, herbals and supplements of Nestlé Health Science (NHSc) to India, is another significant move to strengthen our nutrition and OTC business in India. In Emerging Markets, we have
-
long-establishedand sizeable
OTC business with market-leading products in the allergy, pain relief, gastro-intestinal and women's health categories. We also entered the UK consumer health market with the launch of the OTC allergy medication Histallay this year. A few days ago, we announced the acquisition of the global consumer healthcare brand Nicotinell and its various market-leading brand
Our dossier for our proposed rituximab biosimilar candidate received a Complete Response Letter from the USFDA. We will continue to work closely with the USFDA to address and resolve all concerns within stipulated timelines in order to make this biosimilar rituximab available
to patients in the U.S. as soon as possible. Similarly, the bold and ambitious nature of our ESG goals means that it is challenging to succeed equally in every goal every year.
However, our commitment remains undeterred. By the end of FY2024, we had served over 700 million patients and continue our endeavour to reach over 1.5 billion patients globally by 2030. Our progress was recognised in our ascent to the Dow Jones Sustainability World Index, improved position in the S&P Global Sustainability Yearbook, and Gold Medal status by EcoVadis. In FY2024, we also launched Womb to the World,
would like to build an organisation that will last 500 years.
K Satish Reddy | G V Prasad |
Chairman | Co-Chairman and |
Managing Director |
08
09
Integrated Annual Report 2023-24
Our Global Presence
A global snapshot of our capabilities - through our presence in research, sales and manufacturing around the world, products in 76 countries, and employees representing
53 nationalities, we are able to process, manufacture and take products to patients globally.
Corporate Overview | Strategic Review | Statutory Reports | Financial Statements |
Sales and Other Offices
76 53
CountriesNationalities (Workforce)
US$ 3.35 bn
Revenue
241
Dossiers Filed, including
17 ANDAs + 2 NDAs
Cumulative ANDAs: 325
As of March 31, 2024, 86 filings are pending approval (81 ANDAs and 5 NDAs). Of these, 50 are Para IVs and we believe 24 have 'First-to-File' status.
29.7% | 26,000+ | |||||
EBITDA | Employees Globally | |||||
133 | ||||||
DMFs Filed, including | ||||||
11 DMFs in the U.S.
Cumulative global DMFs: 1,537 including 251 in the U.S.
Research and Development Centres
Manufacturing Facilities
Headquarters
Note: The map is not to scale and is an artistic representation.
All information as of FY2024
181 | 20 | 42 | 106 | 13 | ||||||||||||
Launches | NAG | Europe | Emerging Markets | India | ||||||||||||
10 | 11 |
Integrated Annual Report 2023-24
Key Performance Indicators
Key Financial Performance Indicators
Corporate Overview Strategic Review Statutory Reports Financial Statements
Key Non-Financial Performance Indicators
Revenue | Gross Profit | EBITDA | ||||||||||||||||||
(` Mn) | (` Mn) | (` Mn) | ||||||||||||||||||
FY2024 | FY2024 | FY2024 | ||||||||||||||||||
279,164 | 163,607 | 83,013 | ||||||||||||||||||
FY2023 | FY2023 | FY2023 | ||||||||||||||||||
245,879 | 139,343 | 73,081 | ||||||||||||||||||
FY2022 | FY2022 | FY2022 | ||||||||||||||||||
214,391 | 113,840 | 51,400 | ||||||||||||||||||
FY2021 | FY2021 | FY2021 | ||||||||||||||||||
189,722 | 103,077 | 47,386 | ||||||||||||||||||
FY2020 | FY2020 | FY2020 | ||||||||||||||||||
174,600 | 94,009 | 46,432 | ||||||||||||||||||
PBT | PAT | Net Worth | ||||||||||||||||||
(` Mn) | (` Mn) | (` Mn) | ||||||||||||||||||
FY2024 | FY2024 | FY2024 | ||||||||||||||||||
71,870 | 55,684 | 280,550 | ||||||||||||||||||
FY2023 | FY2023 | FY2023 | ||||||||||||||||||
60,367 | 45,067 | 230,991 | ||||||||||||||||||
FY2022 | FY2022 | FY2022 | ||||||||||||||||||
32,298 | 23,568 | 190,527 | ||||||||||||||||||
FY2021 | FY2021 | FY2021 | ||||||||||||||||||
26,413 | 17,238 | 173,062 | ||||||||||||||||||
FY2020 | FY2020 | FY2020 | ||||||||||||||||||
18,032 | 19,498 | 154,988 | ||||||||||||||||||
ROCE | EPS | Net Debt to Equity Ratio* | ||||||||||||
(%) | (`) | |||||||||||||
FY2024 | FY2024 | FY2024 | ||||||||||||
35.5 | 334.0 | (0.23) | ||||||||||||
FY2023 | FY2023 | FY2023 | ||||||||||||
34.6 | 270.9 | (0.21) | ||||||||||||
FY2022 | FY2022 | FY2022 | ||||||||||||
19.6 | 141.7 | (0.08) | ||||||||||||
Dossiers Filed
Including ANDAs
(Nos.)
FY2024241
FY2023
195
Patients Reached
(Mn)
FY2024~704
FY2023
~689
CarbonNeutrality
(%)
FY2024 | ||
48 | ||
FY2023 | ||
30 | ||
Gender Diversity
DrugMaster File (DMF)
(Nos.)
FY2024
133
FY2023
134
Beneficiaries
underCSR activities
(Nos.)
FY2024 ~497,000
FY2023 ~330,000
Renewable Power
(%)
FY202456
FY2023
42
Board Independence
FY2021 | FY2021 | FY2021 | ||||||
17.8 | 103.6 | (0.04) | ||||||
FY2020 | FY2020 | FY2020 | ||||||
12.2 | 117.4 | (0.03) | ||||||
*Net debt/equity computation excludes lease liabilities, FY2021 onwards.
(%)
FY2024
FY2023
21
18
(%)
FY2024
FY2023
82
78
12 | 13 |
Integrated Annual Report 2023-24
Highlights of the Year - in Pictures
1 | 2 |
5
Corporate Overview | Strategic Review | Statutory Reports | Financial Statements |
3 | 4 |
6 | 7 |
8 | 9 |
1) Second annual | 2) Our strategic | 3) Our China team's | 4) Our Community | 5) Our Brazil team, |
Dr. Anji Reddy Memorial | collaboration with Alvotech | debut at the sixth | Health Intervention | on the launch of |
Lecture delivered by | for AVT03 (denosumab) | China International | Programme (CHIP) in | Lenangio® (Lenalidomide) |
Nobel Laureate | Import Expo (CIIE) | Laveru, Andhra Pradesh | ||
Prof. Jack W. Szostak |
14
- Launch of our Condition Management programme 'DailyBloom™ IBS', India's first-ever digital integrated care plan to manage Irritable Bowel Syndrome (IBS)
- Launch of our Digital Performance Marketing programme, 'Performance X', in collaboration with Indian School of Business (ISB)
- Our CRDMO arm, Aurigene Pharmaceutical Services, opened a new biologics manufacturing facility in Genome Valley, Hyderabad
- Team India ran a Breast Cancer Awareness Month campaign
15
Integrated Annual Report 2023-24
Highlights of the Year -
Awards and Recognitions
Received Gold | Recognised as one of the Top | |||||
First Indian pharma company to | ||||||
Medal status from | 20 Employers among pharma/ | be included in the Dow Jones | ||||
EcoVadis in 2023 | biotech globally for the second year | Sustainability World Index 2023 | ||||
in a row in 2023 | ||||||
Included in S&P Global's | Awarded Excellence in Rural Health | First Indian Pharma |
Sustainability Yearbook 2024 | Initiative at the - 2023 Economic | to receive "A-"in Climate |
in the Top 10% category | Times India Pharmaworld Awards | Change & Water Security by CDP |
Corporate Overview | Strategic Review | Statutory Reports | Financial Statements |
Asia-Pacific
Climate Leader 2024
Technology Strategy Impact | Named by Financial Times | Recognised as 'Company of |
Award 2023 for Asia Pacific | (London) and Statista - as | the Year - Americas' at |
(APAP) by Forrester | Asia-Pacific Climate Leader 2024 | the Global Generics & |
for the second year in a row | Biosimilars Awards 2023 |
ТОП-20 | |||||||||||
2023 год | |||||||||||
Dr. Reddy's | 00 | ||||||||||
О 10 | |||||||||||
ЧЕЛ | |||||||||||
ОВ | |||||||||||
Привлекательный и открытый | ИИ | ||||||||||
ПМ | |||||||||||
НА | |||||||||||
работодатель, успешно развивающий | ОК Е | ||||||||||
HR-процессы и имидж компании | |||||||||||
h.ru/ | |||||||||||
Recognised in the 'Leadership' | Recognised as Top Employer in | CSR Excellence Award 2023 by | |||||||||
category at the - 2023 Institutional | Russia in HeadHunter's Best | the Institute of Company | |||||||||
Investor Advisory Services (IiAS) | Employer Ranking for 2023 | Secretaries of India (ICSI) | |||||||||
Governance Award | |||||||||||
Best Patient Support | Great Place to Work Certification | Golden Peacock Award 2023 in the | Recognised at the India Risk |
Programme at the - 2023 | 2023 - in Colombia, Brazil, China, | pharmaceutical sector - For Excellence in | Management Award 2024 as Masters |
Silver Feather Awards | Malaysia, Thailand, India, Myanmar | Corporate Governance and for Corporate | of Risk - Healthcare and Pharma |
Social Responsibility |
16 | 17 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Dr. Reddy's Laboratories Limited published this content on 02 July 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 July 2024 13:04:06 UTC.